Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
7.5
151.07%
60%
—
21x
Every year
—
5 Years
Score7.5
Net Growth151.07%
Net Trend60%
Net Income Consistency—
Rev Growth21x
Rev TrendEvery year
Revenue Consistency—
Kiniksa Pharmaceuticals Ltd fundamental performance
Between 2020 and 2025, revenue grew from $ 7M to $ 677M and net income went from -$ 161M to $ 59M. Revenue increased in every one of those 5 years; net income in 3.
Kiniksa Pharmaceuticals Ltd currently holds a 5-year HDB Score of 7.5 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 78.15 | — |
1 Year2025-08-12 | $ 32.78 | 138.41% |
5 Years2021-08-12 | $ 12.44 | 6x |
All Time2018-05-24 | $ 19.47 | 301.39% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-05-24 |
|---|---|---|---|---|
| Price | $ 78.15 | $ 32.78 | $ 12.44 | $ 19.47 |
| Return | — | 138.41% | 6x | 301.39% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 840M | $ 80M | $ 525M |
| 2025 | $ 677M | $ 59M | $ 414M |
| 2024 | $ 423M | -$ 43M | $ 243M |
| 2023 | $ 270M | $ 14M | $ 206M |
| 2022 | $ 220M | $ 183M | $ 190M |
| 2021 | $ 38M | -$ 157M | $ 182M |
| 2020 | $ 7M | -$ 161M | $ 323M |
| 2019 | $ 0.00 | -$ 161M | $ 233M |
| IPO2018 | $ 0.00 | -$ 103M | $ 307M |
Explore beyond KNSA
You're looking at Kiniksa Pharmaceuticals Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
